HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat has reiterated a Buy rating on Zevra Therapeutics (NASDAQ:ZVRA) and maintained a $15 price target.
April 03, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Zevra Therapeutics with a $15 price target.
The reiteration of a Buy rating and a maintained price target of $15 by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for Zevra Therapeutics. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100